News & Updates
Showing Infectious Diseases articles
Showing

MTX treatment break improves COVID-19 booster response in patients with IMIDs
In individuals with immune-mediated inflammatory diseases (IMIDs*), a 2-week interruption in methotrexate (MTX) treatment led to enhanced COVID-19 booster vaccine response compared with those who continued with MTX treatment, according to findings from the VROOM** study.

Haemorrhagic complications in COVID-19 patients linked to in-ICU mortality risk
A large global study of patients with severe COVID-19 admitted to the intensive care unit (ICU) has shown a 14 percent prevalence of haemorrhagic, coagulopathic, and thrombotic (HECTOR) complications in these patients, with mortality risk increased in those with haemorrhagic complications.

How effective is ensovibep in hospitalized adults with COVID-19?
Hospitalized patients with COVID-19 who are receiving remdesivir and other standard care show no improvements in clinical outcomes with the addition of ensovibep, according to the results of a study.

Does TB influence viral suppression in HIV patients on DTG-based therapy?
Incident tuberculosis (TB) appears to be a risk factor for virologic non-suppression (ie, viral load of >1,000 copies/mL) in HIV patients who have transitioned to dolutegravir (DTG)-based therapy with recycled NRTIs*, according to a retrospective subanalysis of the VISEND study.

HCV reinfection highest among people with ongoing injecting drug use
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.




